Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Jun 2011
Comparative StudyEnd-of-life care for lung cancer patients in the United States and Ontario.
Both the United States and Canada offer government-financed health insurance for the elderly, but few studies have compared care at the end of life for cancer patients between the two systems. ⋯ NSCLC patients in both Ontario and the United States used extensive end-of-life care. Limited availability of hospice care in Ontario and differing attitudes between the United States and Ontario regarding end-of-life care may explain the differences in practice patterns.
-
J. Natl. Cancer Inst. · Jun 2011
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Acute myeloid leukemia (AML) is a genetically heterogeneous cancer that frequently exhibits aberrant kinase signaling. We investigated a treatment strategy combining sorafenib, a multikinase inhibitor with limited single-agent activity in AML, and cytarabine, a key component of AML chemotherapy. ⋯ Sorafenib in combination with cytarabine resulted in strong anti-AML activity in vitro and in vivo. These results warrant clinical evaluation of sorafenib with cytarabine-based regimens in molecularly heterogeneous AML.